Retatrutide Results: Before and After Trial Outcomes by Week and Dose
Trustworthy retatrutide before and after evidence comes from randomised trials rather than photographs. In the phase 2 obesity study, average weight reduction in the 12 mg arm grew from 17.5% at 24 weeks to 24.2% at 48 weeks, and the phase 3 programme reported 28.3% at 80 weeks. Below, we show how the outcomes develop over time in each trial.
Shop Retatrutide Australia Stock Backed by Trial Data, Not Before and After Photos
Retatrutide results online are full of before and after photos and anecdotal reviews, and very little of it is informative. Retatrutide has no approval in any country, so any use beyond a trial relies on material nobody has verified. Australian regulators have even found retatrutide-branded products with none of the peptide inside. A photo reveals nothing about the contents of the vial.
A randomised trial does. It tests a known dose against placebo across hundreds or thousands of participants, measured at set timepoints. That is the only kind of retatrutide review worth your time, and it is the evidence this page summarises. None of it predicts results for any individual or recommends using the compound.
Order Retatrutide for Research and Review Phase 2 Weight Change at 24 and 48 Weeks
In the phase 2 obesity study (Jastreboff et al., New England Journal of Medicine, 2023), 338 adults with obesity, or with overweight and a related condition, were randomised to weekly retatrutide or placebo over 48 weeks. The table shows mean weight change from baseline.
| Arm | At week 24 | At week 48 | Share losing 15% or more by week 48 |
|---|---|---|---|
| Placebo | 1.6% | 2.1% | 2% |
| 1 mg | 7.2% | 8.7% | not stated here |
| 4 mg (combined) | 12.9% | 17.1% | 60% |
| 8 mg (combined) | 17.3% | 22.8% | 75% |
| 12 mg | 17.5% | 24.2% | 83% |
Two findings are worth highlighting. From week 24 to week 48, the higher-dose arms continued to lose weight, and the investigators observed that no plateau had been reached by the end of the study. In addition, the 12 mg arm saw 83% of people reach a loss of 15% or more, 93% reach 10% or more, and all of them reach at least 5%. Labs benchmarking against those arms can buy retatrutide online in Australia in 10, 20 or 30 mg vials.
Buy Retatrutide Online With a Clear View of How Long It Takes to Work
How long does it take for retatrutide to work? That depends on the outcome being measured, and the trials provide three answers.
- Weight. The curves pull away from placebo early, but the big figures take months to appear. The 12 mg arm sat at 17.5% at 24 weeks, 24.2% at 48 weeks and 28.3% at 80 weeks in phase 3.
- Blood glucose. In the phase 2 type 2 diabetes study, the primary endpoint fell at 24 weeks, by which point HbA1c had dropped by as much as 2.02 percentage points on 12 mg.
- Liver fat. Most of the decrease had already occurred by 24 weeks (82.4% on 12 mg), and it was maintained at 48 weeks.
How long does it take for retatrutide to suppress appetite? Appetite was not reported as a separate early endpoint in the published trials, so no dependable figure exists. GLP-1 receptor activity generally curbs appetite fairly fast, yet trial participants also followed a gradual escalation that intentionally kept early doses low. Any claim pinning it to a precise number of days does not come from the published evidence.
Shop Retatrutide for Sale With the Phase 3 TRIUMPH and TRANSCEND Results in Hand
Phase 3 is far bigger and runs much longer. These are the headline results reported to date.
| Study | Participants | Duration | Outcome reported |
|---|---|---|---|
| TRIUMPH-1 | 2,339 adults with obesity or overweight, no diabetes | 80 weeks | Weight loss of 19.0% (4 mg), 25.9% (9 mg) and 28.3% (12 mg) |
| TRIUMPH-1 extension | 532 participants with a BMI of 35 or more | 104 weeks | 30.3% with 12 mg |
| TRIUMPH-4 | 445 adults with obesity and knee osteoarthritis | 68 weeks | 28.7% with 12 mg versus 2.1% with placebo |
| TRANSCEND-T2D-1 | 537 adults with type 2 diabetes | 40 weeks | HbA1c lowered by 1.7 to 2.0 points, and weight lowered by 11.5% to 16.8% |
| TRIUMPH-2 and TRIUMPH-3 | Obesity alongside type 2 diabetes, or alongside cardiovascular disease | 80 weeks | Roughly 21% and 23% on the top doses |
Most of these figures are toplines from Lilly announcements, while TRANSCEND-T2D-1 appeared in The Lancet (2026). In our view the 80-week TRIUMPH-1 result is the one to quote rather than the 30.3%. The 104-week figure reflects a subgroup with a higher starting BMI who completed the main trial, which makes it an unfair headline.
Order Retatrutide Research Vials Informed by the Liver Fat and Glycaemic Data
In the liver fat substudy (Sanyal et al., Nature Medicine, 2024), researchers tracked 98 participants from the obesity trial who had fatty liver disease. Relative liver fat reductions after 48 weeks were 86.0% with 12 mg, 81.7% with 8 mg, 59.0% with 4 mg and 51.3% with 1 mg, compared with 4.6% on placebo. By 24 weeks, 86% of the 12 mg arm had reached normal liver fat below 5%, while nobody on placebo had. This is the area where the glucagon component is believed to contribute most.
For type 2 diabetes, the phase 2 study (Rosenstock et al., The Lancet, 2023) found HbA1c reductions at 24 weeks of 1.30% to 2.02% at 4 mg and higher, versus almost no change on placebo. It also found body weight reductions reaching about 16.9% at 36 weeks with no obvious plateau. Phase 3 TRANSCEND-T2D-1 produced results in a similar range. People with diabetes reliably lose less weight on incretin drugs than people without it, which accounts for the lower figures in TRIUMPH-2. The retatrutide pen is for sale in Australia as well, holding 10 mg in 3 mL of solution for teams that skip reconstitution.
Buy Retatrutide for Laboratory Research Using These Results as a Benchmark
For a research team, these trial outcomes describe what a positive control ought to look like and which receptor contributions deserve to be separated out. Read our explainer on how retatrutide works for the receptor balance, and the trial side effect data for tolerability at each dose.
At the bench, freeze-dried vials are reconstituted using bacteriostatic water for peptides and measured with U-100 insulin syringes. Our retatrutide reconstitution calculator calculates concentration per unit for every vial size, and the research library holds the PubMed citations this page draws on.
Shop Retatrutide Online in Australia and Pick the Right Vial Size
Benchmark figures like these influence an order as much as the protocol itself, and the key purchasing choice is the fill size. The 10 mg retatrutide vial fits a pilot or a single dose-response curve, while the 20 mg or 30 mg fill makes sense when a longer series needs to run from one lot under one certificate. First-time buyers frequently choose the Retatrutide Starter Kit, which adds diluent and a single U-100 syringe to the peptide for only a little more than the vial by itself. If your study design calls for a dual-agonist reference arm, add tirzepatide in a 2 mg vial to the same order. Order everything online from Australian stock and check the lot on each certificate before the work begins.
NovaPep sells retatrutide to adults 18+ for laboratory research only, not for human or veterinary use. The outcomes described above are published study findings and are not guidance of any kind.
Retatrutide Results: Before and After Trial Outcomes by Week and Dose FAQ
How quickly does retatrutide start working?
In the phase 2 obesity study, weight loss was already considerable by 24 weeks (17.5% on 12 mg) and continued climbing to 24.2% by 48 weeks with no plateau. Improvements in HbA1c for type 2 diabetes were assessed at 24 weeks, and most of the liver fat reduction had occurred by 24 weeks too. These figures are trial averages and do not predict individual outcomes.
How much weight was lost on retatrutide each week?
Trials report total change at set timepoints instead of weekly rates. Roughly speaking, the phase 2 group on 12 mg lost 17.5% during the first 24 weeks and another 6.7 points across the following 24, so the pace slowed with time. Weight loss did not follow a straight line, and individual outcomes varied considerably around the mean.
What are the strongest retatrutide results so far?
The TRIUMPH-1 extension produced the largest reported average, 30.3% after 104 weeks at the 12 mg dose, though this came from a subgroup starting at a BMI of 35 or more who finished the main trial. A fairer headline is the core TRIUMPH-1 result of 28.3% at 80 weeks on 12 mg, which Lilly announced in May 2026.
Can you trust retatrutide before and after photos?
No. Because retatrutide is unapproved, photos posted online come from people using unverified products, and the TGA has identified Australian products labelled retatrutide that actually held another drug. Photos also reveal nothing about dose, duration or diet. Only randomised, placebo-controlled trials provide reliable retatrutide results.
Where can I order retatrutide online for research in Australia?
NovaPep offers it online strictly for laboratory research. Choose a starter kit, a 10 mg pen, or a freeze-dried vial filled at 10, 20 or 30 mg, with every option dispatched from Australian stock. An outside laboratory checks every lot for identity by mass spectrometry and purity by HPLC, so choose the fill that matches your study and review its certificate in the COA library before ordering.